ArticleProstate cancer2024

Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors.

Kazuro Kikkawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.